GSK’s Promacta Cleared For Use With Interferon In Hep C Patients
This article was originally published in The Pink Sheet Daily
The new indication fills an unmet need in a population of patients who have a short window to cure chronic hepatitis C infection before liver damage becomes too great for treatment, but for whom interferon-based therapy – currently their only option - is not indicated because of low platelet levels.
You may also be interested in...
The president of GlaxoSmithKline Oncology talked with “The Pink Sheet” about precision medicine, regulatory climate change, the need to provide value for payers and the company’s commitment to double cancer survival globally over the next 10 years.
Much of the hep C wish list was on display at the American Association for the Study of Liver Disease meeting in Boston Nov. 10-13 – all-oral interferon-free drug combinations for hepatitis C, regimens that don’t require ribavirin, and the possibility of a one-pill, once-a-day cure – demonstrating the Gold Rush mentality in the hep C space as drug makers race to put the pieces together and grab a share of a burgeoning market.
GlaxoSmithKline’s thrombocytopenia treatment for patients with idiopathic thrombocytopenic purpura will launch the week of Nov. 24.